Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Alterity Therapeutics logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Key Stats

Today's Range
$1.07
$1.10
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
9,597 shs
Average Volume
130,956 shs
Market Capitalization
$9.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRAN Stock News Headlines

Alterity Therapeutics Advances in Neurodegenerative Drug Trials
Alterity Therapeutics Appoints New Company Secretary
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Alterity Therapeutics appoints Abby Macnish Niven as secretary
Alterity Therapeutics Unveils New Advances for MSA Tracking
Alterity Therapeutics announces new publication on ATH434
Alterity Therapeutics: Innovative Approach with ATH434
Alterity Therapeutics Reveals Positive MSA Trial Data
See More Headlines

PRAN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Book Value
$1.40 per share

Miscellaneous

Free Float
N/A
Market Cap
$9.35 million
Optionable
Not Optionable
Beta
1.05
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:PRAN) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners